Mesenchymal stem cells (MSCs) have emerged as a potential therapy for a range of neural insults. In animal models of multiple sclerosis, an autoimmune disease that targets oligodendrocytes and myelin, treatment with human MSCs results in functional improvement that reflects both modulation of the immune response and myelin repair. Here we demonstrate that conditioned medium from human MSCs (MSC-CM) reduces functional deficits in mouse MOG 35-55 -induced experimental autoimmune encephalomyelitis (EAE) and promotes the development of oligodendrocytes and neurons. Functional assays identified hepatocyte growth factor (HGF) and its primary receptor cMet as critical in MSC-stimulated recovery in EAE, neural cell development and remyelination. Active MSC-CM contained HGF, and exogenously supplied HGF promoted recovery in EAE, whereas cMet and antibodies to HGF blocked the functional recovery mediated by HGF and MSC-CM. Systemic treatment with HGF markedly accelerated remyelination in lysolecithin-induced rat dorsal spinal cord lesions and in slice cultures. Together these data strongly implicate HGF in mediating MSC-stimulated functional recovery in animal models of multiple sclerosis. npg
a r t I C l e S Multiple sclerosis is an autoimmune disease that results in progressive functional deficits. The initial course of the disease is characterized by relapsing and remitting episodes that frequently progress to a more chronic functional loss 1 . The target of immunological attack appears to be myelin sheaths, and the loss of myelin and death of myelinating oligodendrocytes leaves axons functionally compromised and vulnerable to damage 2 . Most therapies for multiple sclerosis are directed toward suppression of the immune response; however, longterm functional recovery is likely to depend on the ability of the CNS to replace lost oligodendrocytes and repair myelin sheaths damaged by disease. The realization that the adult CNS retains a population of oligodendrocyte precursors 3 , as well as more multipotent neural stem cells 4 , has encouraged the development of therapies oriented toward myelin repair.
The use of animal models such as EAE have facilitated the development of new therapeutic approaches for multiple sclerosis, as well as our understanding of the pathobiology of demyelinating diseases. Induction of EAE by immunization with peptides of myelin oligodendrocyte glycoprotein (MOG) results in chronic functional deficits that are correlated with areas of demyelination and inflammation in white matter tracts, particularly in the spinal cord. Likewise, the use of local chemically induced demyelination such as that resulting from the injection of lysolecithin (LPC) or ethidium bromide has illuminated the details of myelin repair.
Cell-based therapies are emerging as an important approach to the treatment of multiple sclerosis 5, 6 . Whereas most therapies are directed toward modulation of the immune system, cell-based therapies offer the possibility of localized multifaceted influences that promote effective remyelination during the course of the disease concomitant with modulation of immunological attack 6 . Several stem cell populations have shown therapeutic promise in the setting of different neural insults. For example, neural stem cells promote repair in models of multiple sclerosis 5, 7 , and adult oligodendrocyte progenitors identified by expression of the proteoglycan NG2 (NG2 + cells) enhance axonal regeneration after spinal cord injury 8 . One of the most intensively studied stem cell populations in the context of tissue regeneration is MSCs 9 . Initial work identified MSCs as a powerful regulator of graft-versus-host disease (GVHD) after bone marrow stem cell transplants 10 , and more recently they are emerging as a promising approach for cell-based therapies for several neurological disorders, including stroke 11 , spinal cord injury 12 , multiple sclerosis 6, 13, 14 and other demyelinating diseases 15 .
In animal models of multiple sclerosis, the efficacy of MSCs at enhancing functional recovery appears to reflect their ability to modulate both the immune system and neural cell responses 13, 16 . In EAE, treatment with MSCs results in a biasing of the immune response from proinflammatory T H 1-based to anti-inflammatory T H 2-based responses 13 . In addition, MSCs localize to the areas of demyelination in the CNS and promote functional recovery. Although MSCs have been proposed to have the capacity to give rise to neural cells 17 in the setting of demyelination, their primary function appears to be the promotion of endogenous repair mechanisms 13 that we show can be recapitulated by conditioned medium, suggesting it reflects the release of soluble factors.
The molecular mechanisms responsible for functional recovery in EAE following treatment with MSCs have not been identified.
Here we show that the effects of MSCs reside in a fraction of MSC-conditioned medium a critical component of which is HGF. HGF is a pleiotropic cytokine made primarily by cells of mesenchymal origin. Originally described as a mitogen for hepatocytes 18 , HGF has been identified in many different tissues, including the CNS 19 . In general, HGF is thought to promote angiogenesis and cell survival 20, 21 , and injection of HGF has been demonstrated to enhance kidney and liver regeneration, as well as protect against the onset of renal failure 22 . The effects of HGF are not restricted to liver and kidney, and it has been shown to prolong the survival of cardiac allografts and improve myocardial function after myocardial infarction 23 .
The biological effects of HGF are primarily mediated by the tyrosine kinase transmembrane receptor cMet 24 . During development, cMet is expressed in several different tissues, including the CNS 25 and liver. Expression in liver is retained in normal adult and activated during parenchymal regeneration in adult mice 26 , consistent with a role for this pathway in tissue regeneration.
In this study we identify a central role for the HGF-cMet signaling pathway in mediating functional recovery and remyelination stimulated by MSCs. Human MSCs in growth conditions secrete HGF, and their capacity to promote recovery in EAE depends on signaling through the cMet receptor. The beneficial effects of both MSC-CM and HGF in EAE are selectively blocked by treatment with functionblocking cMet and with antibodies to HGF (anti-HGF). Systemic treatment with HGF markedly accelerates the rate of remyelination in a non-immune-mediated spinal cord LPC lesion model of demyelination and in cerebellum slice cultures. These data support the notion that a major role of MSCs is to provide a source of trophic factors 14 , including HGF, that modulate the inflammatory environment in demyelinating diseases and stimulate endogenous neural cell remyelination to enhance functional recovery.
RESULTS

MSC-CM modulates neural development and disease in EAE
Long-term functional recovery in demyelinating disease depends on myelin repair and suppression of pathogenesis, both of which appear to be influenced by MSCs. To determine whether the neural responses and functional recovery seen after treatment of animals infused with MSCs reflect release of soluble factors, we assayed the effects of MSCconditioned medium (MSC-CM) on neural cell development and functional recovery. Exposure of neurosphere cultures to MSC-CM resulted in a reduction in the proportion of astrocytes and an increase in the proportion of antibody A2B5 + oligodendrocyte precursor cells (OPCs), oligodendrocytes and neurons that developed ( Fig. 1a) . In control cultures after 3 d in vitro, approximately 30% of cells were glial fibrillary acidic protein (GFAP)-positive astrocytes and A2B5 + OPCs, 25% were O4 + immature oligodendrocytes and less than 5% neurons.
By contrast, after 72 h in MSC-CM, the proportion of astrocytes was reduced to 20%, and the proportion of O4 + cells (50%) and neurons (25%) increased significantly ( Fig. 1b ; P < 0.05).
Injection of MSC-CM rapidly reduced the disease load in EAE mice ( Fig. 1c) . Injection of MSC-CM 17 d after MOG immunization, at the peak of disease, resulted in a rapid reduction in functional deficits in 11 of 11 mice. Whereas control mice maintained a clinical score between 2.5 and 3, where 0 is unaffected and 5 is dead or moribund, all mice that received MSC-CM showed some functional improvement. Four of the 11 mice improved to a clinical score of 1 and two other mice appeared completely normal within 5 d. This functional recovery was correlated with a reduction in the extent of regions of demyelination seen in spinal cord sections stained with luxol fast blue ( Fig. 1d) .
MSC-CM stimulated recovery depends on a 50-100-kDa activity
Size fractionation studies demonstrated that the disease-modifying activity of MSC-CM required a fraction with a molecular mass between 50 and 100 kDa. Fractions with masses 1-50 kDa did not significantly modify disease progression in MOG EAE in vivo (data not shown). By contrast, 1-100-kDa (MSC-CM 100kDa ) fractions reduced disease burden in the EAE model (n = 11) ( Fig. 2a ) and increased the proportion of oligodendrocytes and neurons from neurosphere cultures ( Fig. 2b) . This functional improvement was correlated with improvements in the histology of the spinal cord that were comparable to those seen with complete MSC-CM. Injection of unconditioned control medium or heat-inactivated MSC-CM (n = 8) had no obvious effect on either functional outcome or histology. Fig. 2c) . At day 35 after EAE onset, the level of the proinflammatory cytokines interferon-γ (IFN-γ), interleukin (IL)-17, tumor necrosis factor-α (TNF-α), IL-2 and IL-12p70 were decreased in mice that received MSC-CM 100kDa , whereas levels of anti-inflammatory cytokines such as IL-10 and IL-4 were increased.
Recombinant HGF modulates disease progression in EAE
On the basis of the size fractionation studies, known MSC expression data 27, 28 and previously described biological properties 29, 30 , we identified HGF as a candidate molecule in the MSC-CM 100kDa fraction that could modulate disease in EAE. Western blot analyses of active MSC-CM 100kDa identified HGF (molecular mass, 62 kDa α chain + 34 kDa β chain) at a concentration of between 600 and 800 ng ml −1 in all active samples (n = 6) but not in unconditioned control medium ( Fig. 3a) . To determine whether recombinant HGF treatment could promote functional recovery in EAE, mice at the peak of disease (clinical score = 3) received injections of either PBS (n = 10) or HGF at two different concentrations (50 and 100 ng per mouse, n = 10 each) every other day over a 5-d period (days 1, 3 and 5) and their clinical scores were monitored for 30 d after immunization. The clinical scores of control npg a r t I C l e S mice remained relatively constant between 3-3.5, whereas mice that received HGF improved (Fig. 3b) . The higher dose of HGF appeared to provide slightly better functional recovery, although both doses reduced the mean functional score below 1.5 (Fig. 3b) . The functional improvement after intraperitoneal (i.p.) injection of HGF (100 ng) was less than that after i.v. injection. For example, at 30 d after immunization the mean score of i.p.-treated mice was approximately 2.4, as compared to 1.5 for i.v. treated animals (Fig. 3b) . All subsequent studies used i.v. delivery. The HGF-induced functional improvement was closely correlated with histological improvement. In control EAE mice, luxol fast blue staining revealed extensive regions of white matter pathology along the length of the spinal cord 30 d after immunization (Fig. 3c) . In HGF-treated mice at the same stage, the degree of demyelination was markedly reduced and most white matter appeared relatively normal ( Fig. 3c) . Inflammatory cell infiltration in EAE mice was also reduced in HGF-treated animals. In control EAE mice, hematoxylin and eosin staining revealed white matter regions with a high density of infiltrated cells (Fig. 3c) , and labeling with antibodies to CD3 confirmed this (Fig. 3c) . Both the extent of the infiltrate and the density of cells were reduced in mice treated with HGF. Myelin integrity was confirmed in 1-µm Epon resin sections labeled with toluidine blue and by ultrastructural analyses (Fig. 3c ) that demonstrated a decrease in the number of unmyelinated axons. In lesion areas of EAE mice a majority of axons were unmyelinated (80 ± 20%), whereas in lesion areas of HGF-treated EAE mice a minority (10 ± 4% P = 0.05) were unmyelinated. Analyses of myelin thickness in lesion areas showed that HGF treatment resulted in substantially thicker myelin sheaths npg a r t I C l e S around small-diameter axons, as well as an increase in the relative number of small-diameter (<1 µm) axons (Fig. 3d) . Together these studies suggest that treatment of EAE mice with HGF results in substantial functional improvement and an enhancement in the extent of spinal cord remyelination.
To examine the timing of HGF-induced histological improvement, we assessed histology of mice on 1-µm sections at the time of treatment initiation and 3, 11 and 17 d thereafter. Spinal cords had extensive demyelinated lesions and cellular infiltrates at initiation of treatment that were still apparent after 3 d of treatment (Supplementary Fig. 1) . After a further 8 d, the lesions were largely resolved, although there was a residual elevated cellularity. By 17 d after initiation of treatment, light microscopy ( Fig. 3c) and ultrastructural analyses (Fig. 3c) revealed extensive remyelination in HGFtreated mice, with essentially all fibers, including small-diameter fibers, extensively myelinated. These data suggest HGF both reduces pathological pressure and enhances or facilitates myelin repair.
HGF-and MSC-CM-stimulated recovery is mediated by cMet
In other systems the biological properties of HGF are mediated through the tyrosine receptor kinase cMet, the best characterized receptor for HGF 31 . To determine whether the functional benefits of HGF in EAE were also mediated by cMet, we treated EAE mice with a function-blocking cMet antibody 32, 33 (250 ng twice per mouse i.v., 24 h before HGF treatment). In mice that received control immunoglobulin G followed by three injections of HGF at the peak of disease (n = 8), functional improvements were evident after 24 h that plateaued after 5-7 d (Fig. 4a) . By contrast, mice treated with cMet antibodies (n = 10) did not show any substantial improvement over the subsequent 14 d. Histologically the lesions in mice treated with a r t I C l e S cMet antibodies appeared similar to those in controls that did not receive HGF, with only limited remyelination (data not shown). Treatment with cMet antibodies also negated the capacity of HGF to modulate the immune response in EAE mice (Fig. 4) . For example, compared to levels in untreated EAE mice, we detected relatively low levels of the proinflammatory cytokines IFN-γ, IL-17, TNF-α, and IL-2 in HGF-treated animals, and these were elevated in those that received cMet antibodies (Fig. 4c) . Likewise, the levels of anti-inflammatory cytokines IL-10 and IL-4, elevated in HGF-treated mice, were reduced after treatment with cMet antibodies (Fig. 4c) . Enzyme-linked immunosorbent spot (ELISPOT) assays demonstrated that HGF treatment resulted in a reduction in the frequency of spinal cord-derived MOG -specific proinflammatory cytokine (IFN-γ, IL-17)-producing cells and an increase in IL-10-producing cells that was reversed by cMet antibody treatment (Fig. 4e) . These results confirm that, in the setting of EAE, the biological activity of HGF is mediated through cMet.
Treatment with cMet antibodies blocked MSC-CM-mediated functional recovery. In control immunoglobulin G-treated mice (two injections, 24 h before treatment), MSC-CM stimulated a rapid and sustained functional recovery ( Fig. 4b ) (n = 9). By contrast, mice treated with cMet antibodies showed little or no functional improvement over the subsequent 15 d (Fig. 4b) (n = 11). Treatment of MSC-CM with function-blocking anti-HGF for 2 h before injection also inhibited its capacity to reduce functional deficits in EAE (Fig. 4b) . Cytokine analyses revealed that the decrease in proinflammatory cytokines and the increase in anti-inflammatory cytokines associated with MSC-CM were largely reversed by prior treatment with cMet antibodies (Fig. 4d) , as were the alterations in the frequencies of antigen-specific IFN-γ-, IL-17-and IL-10-secreting cells shown by ELISPOT analysis (Fig. 4f) . These data strongly suggest that HGF signaling in MSC-CM is critical for mediating functional recovery and promoting histological improvement in MOG-induced EAE.
cMet mediates HGF/MSC-CM stimulation of neural development
To assess the role of HGF in MSC-CM 100kDa -induced neural cell development, we compared HGF and MSC-CM 100kDa treatment as to their relative generation of the different classes of neural cells from postnatal neurospheres and the dependence on cMet signaling. In control neurosphere-derived cultures grown for 7 d, the proportion of A2B5 + OPCs, O4 + oligodendrocyte lineage cells and β-tubulin + neurons was below 10%, and the proportion of GFAP + astrocytes was greater than 60% (Fig. 5a,b) . By contrast, in the presence of MSC-CM 100kDa the proportion of A2B5 + OPCs was increased to approximately 25%, the proportion of O4 + cells was greater than 30% and the proportion of β-tubulin + neurons was greater than 40%, whereas the proportion of astrocytes was markedly reduced (to ~10%). In both cases, cells tended to form clusters, although this was more prevalent in controls, and total cell numbers were not significantly different in either condition. Similar changes in cell proportions were seen in cultures treated with HGF (45 ng per 3 × 10 5 cells), although the reduction in GFAP + astrocytes was less pronounced with HGF than with MSC-CM 100kDa . Blocking cMet negated the effects of both MSC-CM 100kDa and HGF, and the cellular composition of the cultures reverted to that of controls ( Fig. 5a,b) . Similarly, incubation of MSC-CM 100kDa with function-blocking anti-HGF negated npg a r t I C l e S its effects on neural cell development, consistent with a major role for MSC-CM-derived HGF in the regulation of neural cell development (Fig. 5a,b) .
Repopulation of demyelinated lesions depends on OPCs migration, which can be stimulated by MSCs 34 . To assess whether EAE pathology responses were dependent on cMet, we established neurospheres from the subventricular zones of mice with ongoing EAE and compared cell migration in the presence or absence of MSC-CM 100kDa or HGF with or without cMet-supplemented medium. Cell migration was enhanced in the presence of HGF, and this was inhibited by cMet antibodies (Fig. 5c) . Similarly, cell migration from EAE-derived neurospheres was enhanced by MSC-CM 100kDa , and this effect was blocked by anti-cMet or anti-HGF (Fig. 5d) . Most migratory cells gave rise to either neurons (Fig. 5c,d) or oligodendrocytes (Fig. 5d) , and very few generated astrocytes (data not shown). Consistent with HGF mobilizing OPCs and enhancing remyelination, in vivo EAE lesions of mice treated with HGF contained more than twice as many oligodendrocyte lineage cells identified by expression of the reporter EGFP from the proteolipid protein promoter (EGFP-PLP) (3.1 ± 0.3 per 200 µm 2 ) than lesions of control mice (1.8 ± 0.2 per 200 µm 2 ) (Fig. 5e) . The average number of lesions was also significantly reduced in mice treated with HGF compared to controls. Control EAE mice had 6 ± 0.4 areas of lesion in an average section, and this was reduced to 3.4 ± 0.6 in those treated with HGF (P < 0.05).
HGF promotes repair in non-immune-mediated demyelination
The restitution of histological integrity seen in EAE upon treatment with HGF is likely a combination of suppression of the immune response and the promotion of myelin repair. To determine whether HGF promotes myelin repair in non-immune-mediated demyelination in vivo, we used a spinal cord LPC lesion and slice culture model. In rats injected i.v. with HGF (0.8 µg per kilogram body weight) on days 4, 6 and 11 after an LPC lesion and examined on 14 or 28 days post-lesion (dpl), we saw a 30% reduction in overall lesion volume by luxol fast blue staining compared to that in saline controls (Fig. 6a,b) . Labeling of frozen sections with antibodies to myelin basic protein (MBP) demonstrated only limited expression in control lesions, whereas in the HGF-treated lesions we saw substantial MBP staining throughout the lesion 14 dpl (Fig. 6c,d) . Similarly, the density of NG2 + cells was increased approximately eightfold in HGF-treated lesions (4 ± 2 to 33 ± 5 per cm 2 ; P < 0.005) ( Fig. 6e,f,) and more than 25% of these cells were proliferating as shown by Ki67 double labeling (data not shown). By contrast, whereas control lesions showed an extensive astrocyte response, with intense GFAP labeling around the lesion perimeter, this was substantially attenuated in HGF-treated rats (Fig. 6g,h) .
The increase in NG2 and MBP labeling in the HGF-treated lesions was accompanied by a marked increase in the extent of remyelination ( Fig. 6i-m) . In control lesions (n = 9), few myelinated axons were present in lesions, even at the lesion edge ( Fig. 6i) , whereas in HGF-treated rats (n = 8) myelinated axons were distributed throughout the lesion, interspersed with cells full of myelin debris (Fig. 6j) . Ultrastructural analyses showed that control lesions contained largely unmyelinated axons, some of which were ensheathed in glial processes (Fig. 6k) , whereas in HGF-treated rats, lesions contained axons of different sizes at different stages of remyelination, some with relatively thick myelin sheaths (Fig. 6l) but most with thin myelin (Fig. 6m) . Calculation of the relative thickness of the myelin sheath to axon diameter (G ratio) confirmed the abundance of thinly myelinated axons in HGF-treated lesions (Fig. 6n) and showed a greater than fivefold increase in the density of remyelinated axons (from 18 ± 2 to 130 ± 6 per cm 2 ; P < 0.0002). Treatment with 0.4 µg ml −1 HGF resulted in increased but less profound enhancement of remyelination, and by 28 dpl some limited remyelination was apparent in controls although the beneficial effects of HGF were still evident (data not shown).
Consistent with the HGF-induced functional recovery in LPC lesions, treatment of LPC-demyelinated slice cultures with HGF enhanced recovery. Slices of postnatal day 7 cerebellum myelinated extensively in vitro over a 7-d period (Supplementary Fig. 2a ), and treatment with LPC induced a rapid and sustained demyelination (Supplementary Fig. 2a ). Exposure of LPC-treated slices to 50 ng ml −1 HGF promoted re-ensheathment by oligodendrocytes and reestablished the cytoarchitecture of the slice (Supplementary Fig. 2a) . A lower dose of HGF (10 ng ml −1 ) had little effect, whereas a higher dose (90 ng ml −1 ) resulted in marginal additional improvement. A similar HGF-induced recovery of MBP profiles was seen in slice cultures from cerebral cortex treated with HGF ( Supplementary  Fig. 2a) . Quantification of the extent of myelination of individual oligodendrocytes demonstrated a 2.5-fold decrease after LPC treatment that was largely reversed by HGF treatment (Supplementary Fig. 2b) . This HGF induced functional recovery was negated by exposure to anti-cMet ( Supplementary Fig. 2b) . This recovery likely reflects stimulation of oligodendrocyte development, as addition of 50 ng ml −1 HGF to dissociated cell cultures from postnatal day 0 spinal cord increased the proportion of O4 + and O1 + cells, from approximately 3% (O4 + ) and 1% (O1 + ) in control cultures to greater than 15% (O4 + ) and 23% (O1 + ) after 3 d in HGF (Supplementary Fig. 2c,d) . To confirm the expression of cMet on OPCs, we double-labeled cells with A2B5 and anti-cMet in vitro after 3 d in culture. Virtually all OPCs in culture expressed cMet (Supplementary Fig. 3a-c) . By contrast, in vivo in naive rats very few cells of the oligodendrocyte lineage expressed detectable cMet, whereas in the setting of demyelinating lesions virtually all cells of the oligodendrocyte lineage expressed high levels of cMet ( Supplementary Fig. 3d-f) .
Taken together, these studies suggest that the ability of MSCs to reduce disease burden in models of EAE is dependent on their promotion of HGF signaling that both regulates immunomodulation and enhances remyelination in the setting of demyelinating disease.
DISCUSSION
Recent studies suggest that stem cell-based approaches are promising therapies for the treatment of demyelinating diseases such as multiple sclerosis. Mesenchymal stem cells have emerged as an attractive candidate for the treatment of neurological pathologies on the basis of their effectiveness, relative accessibility, ease of expansion and expression of trophic factors 9 . Previous studies indicated that bone marrow-derived MSCs promoted functional recovery and reduced lesion load in animal models of EAE 6, 13, 35 , and these observations have led to the development of several clinical trials using MSCs for the treatment of multiple sclerosis 36 .
Here we show that in EAE, an animal model of multiple sclerosis, human MSC growth-conditioned medium is effective at promoting functional recovery through a combination of immune suppression and promotion of myelination. Several lines of evidence indicate that these MSC activities depend on the secretion of hepatocyte growth factor (HGF). For example, fractionation studies indicate the activity of MSC-CM mediating functional recovery in EAE is contained in a 50-100-kDa fraction, consistent with HGF with a molecular mass of approximately 62-65 kDa for the α and 34 kDa for the β chain 37 . Treatment of mice after the onset of EAE disease with HGF reduced the severity of disease, and pretreatment with cMet antibodies blocked the effects of both HGF and MSC-CM, while pretreatment with anti-HGF blocked the effects of MSC-CM. The cellular responses to MSC-CM and HGF were similar. npg a r t I C l e S Both stimulated the development and migration of oligodendrocytes and neurons and reduced the emergence of astrocytes from neurosphere cultures. Likewise, both MSC-CM and HGF reduced proinflammatory cytokine expression and enhanced anti-inflammatory cytokine expression, and HGF markedly enhanced remyelination in LPC-induced spinal cord demyelination and promoted ensheathment following demyelination in slice cultures of cerebellum and cortex.
The observations that HGF is required for MSC-CM-mediated functional recovery in EAE is consistent with the observations that MSCs release a variety of growth factors 9 including HGF and that this can be enhanced by stimulation with epidermal growth factor or TNF-α 28 . In many different conditions the biological effects of MSCs and HGF are similar. For example, in GVHD, a major complication that follows transplantation of allogeneic bone marrow, MSCs provide robust benefit, reducing the incidence of GVHD 38 , and in a mouse model of GVHD, transfection of human HGF into skeletal muscle was found to inhibit damage to the gut and liver and enhance survival 39 . Similarly, MSCs appear to show promise for the treatment of myocardial infarcts, and transfection of HGF directly into the myocardium in a mouse model of autoimmune myocarditis reduced disease burden through a reduction in cardiomyocyte apoptosis and through induction of T H 2 anti-inflammatory cytokines 40 . Finally, a recent study demonstrated that mice in which expression of HGF was driven from a neuronal specific promoter were resistant to EAE owing to tolerization of dendritic cells and induction of T H 2 cytokines 41 , consistent with previous studies using MSC treatments in EAE 13, 42 .
Mesenchymal stem cells and HGF influence similar cellular targets in both the CNS and immune system. In the CNS, HGF is expressed both during development and in the adult, where it has been suggested to act as a neurotrophic factor 19 . Consistent with this hypothesis, cMet is expressed on a range of neuronal populations 19 , and cMet stimulation promotes axon outgrowth and neuronal differentiation in many neuronal populations 29 . The expression of cMet and the effects of HGF are not restricted to neurons. Astrocytes, microglia and oligodendrocyte precursors have been shown to express cMet 30, 43 . The expression of cMet on oligodendrocyte lineage cells appears to be environmentally regulated. Whereas most OPCs are cMet + in vitro and in lesions of the CNS, they are cMet − in naive tissue. In humans the expression of cMet is less well characterized, but it has been described on some CNS tumor cells and microglia 8, 43 . Which of these cellular targets are critical for the myelin repair seen in HGF-or MSC-CM-treated animals is unknown. Likewise, in the immune system, dendritic cells express cMet, and HGF induces tolerance in this cell population 41 . Both MSC-CM and HGF bias T cells away from T H 1 and toward T H 2 responses, as well as regulating the expression of IL-10 (ref. 41 ). The relative contributions of HGF-mediated modulation of immune response and local stimulation of myelin repair are unclear. However, the rapid, widespread remyelination of spinal cord LPC lesions seen after HGF treatment suggests that HGF promotes myelin repair in the absence of modulating the immune system. For example, although LPC injection does induce an immune response, it results in a rapid but brief influx of immune cells between 6 and 48 h (ref. 44 ). In the current studies, we delayed treatment with HGF until 5 dpl, a time when the lesion has mostly developed. In general, remyelination follows recruitment of OPCs to the lesion area and occurs over a 3-to 5-week period 45 . By contrast, in HGF-treated rats robust remyelination was apparent throughout the lesion by 14 dpl and only 9 d after the commencement of treatment. This rapid repair suggests that HGF both recruits OPCs and enhances remyelination.
The beneficial effects of transient HGF treatment are sustained in EAE. The reduced EAE disease burden in mice that constitutively express HGF from the neuron-specific enolase promoter may reflect the continuous expression of elevated HGF. In the current studies, however, a series of three injections of HGF at the peak of disease resulted in functional and histological recovery that was sustained for up to 2 weeks, the longest time examined. Although HGF is known to pass across the blood brain barrier 46 , given that its half-life is thought to be relatively short after injection 46 , the mechanisms that result in this long-term benefit are unclear. It may be that a short period of stimulated recovery is sufficient to inhibit further pathogenesis by permanently shifting the balance of pathological pressure and in favor of repair 47 . Alternatively, in other systems it has been demonstrated that elevation of exogenous HGF results in sustained elevation of endogenous HGF through a proposed positive feedback auto loop 48 . Finally, the effect of HGF may be to alter the balance of pro-and anti-inflammatory T cells in EAE on a long-term basis, possibly by influencing dendritic cell secretion of IL-23. If such a mechanism were operative, it could explain persistent recovery.
A function for HGF in multiple sclerosis has not been defined. Previous studies suggest that in patients with multiple sclerosis, as well as those with other neurological diseases, the HGF is elevated in cerebrospinal fluid. Although this has been proposed to correlate with pathology, particularly demyelinating pathology, our studies suggest it is more likely a reflection of an endogenous repair process stimulated by the disease. Indeed, it may be that susceptibility or disease progression in multiple sclerosis is, in part, a reflection of the capacity of endogenous MSCs to release HGF. Consistent with this hypothesis, Hgf gene expression decreases with age in mouse MSCs, and although MSCs from patients with multiple sclerosis have similar proliferative, differentiative and cell surface properties to control MSCs, they differ in their cytokine profiles.
In conclusion, we show that the therapeutic efficacy of MSCs in EAE is a result of secreted signals that are found in growthconditioned medium. The biological effects of the conditioned medium depend on the presence of HGF, and sustained functional recovery in EAE follows a transient treatment with exogenously supplied HGF. The effects of both HGF and MSC-CM are mediated through the tyrosine kinase receptor cMet and include enhanced myelin repair as well as immunomodulation. These studies raise the possibility that the HGF-cMet pathway may provide new therapeutic opportunities for the treatment of multiple sclerosis.
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